KUALA LUMPUR: The supply of medicines in Malaysia is stable and under control, says the Health Ministry, which gave the assu\u00adrance based on a current assessment of supply in the country.<\/p>\n
\u201cWe keep between one and three months of medicine stock at our facilities based on usage req\u00aduirements.<\/p>\n
\u201cWe are supported by an additional two-month buffer at the con\u00adcessionaire level for medicines supplied through concession arrangements,\u201d said the ministry in a statement yesterday.<\/p>\n
As such, it said that the impact from the Middle East conflict in the short term is minimal.<\/p>\n
\u201cThe ministry will continue to monitor the conflict in the Middle East closely,\u201d it added.<\/p>\n
Overall, the ministry said the monitoring of the domestic drug supply is carried out continuously through existing mechanisms, including a system for reporting supply disruptions from the \u00adPro\u00ad\u00adduct Registration Holder (PRH) operated by the National Phar\u00admaceutical Regulatory Agency.<\/p>\n
As of Sunday, the ministry said no increase has been detected in reports from PRH regarding supply interruptions.<\/p>\n
\u201cFeedback from the local pharmaceutical industry indicates that domestic manufacturers hold raw material stocks for up to three months and finished products for about two months.<\/p>\n
\u201cImporters are closely monitoring their respective supply chains as well.\u201d<\/p>\n
The ministry pledged to take proactive measures, which inclu\u00added forming a taskforce with representatives from the pharmaceutical industry and other relevant stakeholders.<\/p>\n
\u201cThis is to ensure the security of the medicine supply, particularly for items under the Natio\u00adnal Essen\u00adtial Medicines List,\u201d it said.<\/p>\n","protected":false},"excerpt":{"rendered":"KUALA LUMPUR: The supply of medicines in Malaysia is stable and under control, says the Health Ministry, which…\n","protected":false},"author":3,"featured_media":678645,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[210,148828,8371,8372,1060,285697,266496,44066,26840,34658,285695,285696,67,132,68],"class_list":["post-678644","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-health-ministry","tag-kuala-lumpur","tag-malaysia","tag-medication","tag-medicine-stock","tag-middle-east-conflict","tag-monitoring","tag-pharmaceutical-industry","tag-stable","tag-supply-of-medicines","tag-under-control","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116284946217264239","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/678644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=678644"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/678644\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/678645"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=678644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=678644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=678644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}